Andrew A Young

This inventor holds 68 USPTO granted patents and 18 published patent applications, plus 2 CIPO patents and 9 EPO patents, primarily in Diabetes Treatments (CPC class A61K). Top assignees: Amylin Pharmaceuticals, Inc., Satiogen Pharmaceuticals, Inc., Astrazeneca Pharmaceuticals LP. Active years: 1993-2023.

USPTO Granted Patents = 68 (Patent Applications = 18)

% Patents Active = 54.4

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 9 (Patent Applications = 13)

Average Co-Inventor Count = 2.8

ph-index = 30

Forward Citations = 2,217(Granted Patents)

Forward Citations (Not Self Cited) = 2,027(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Alpine, CA (US) (1998 - 2008)
Rancho Sante Fe, CA (US) (2010)
La Jolla, CA (US) (2005 - 2012)
Rancho Santa Fe, CA (US) (2006 - 2013)
San Diego, CA (US) (1993 - 2015)
Chapel Hill, NC (US) (2012 - 2022)
Research Triangle Park, NC (US) (2012 - 2023)
Boston, MA (US) (2020 - 2023)

Company Filing History:

53 out of 164

Amylin Pharmaceuticals, Inc.

patents

9 out of 9

Satiogen Pharmaceuticals, Inc.

patents

7 out of 39

Astrazeneca Pharmaceuticals LP

patents

4. 4 out of 68

Intarcia Therapeutics, Inc.

patents

5. 1 out of 8

I2o Therapeutics, Inc.

patents

6. 1 out of 834,350

Other

patents

where one patent can have more than one assignee

Years Active: 1993-2023

Loading Chart...

Areas of Expertise:

Glucagon-Receptor Polypeptides

Bile Acid Inhibitors

Exendin Agonists

Diabetes

Obesity

GIP Analog

Amylin Agonists

Polycyclic Ovary Syndrome

Gastrointestinal Motility

Peptide Therapy

Satiogens

DPP-IV Resistant

68 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11840559 - Glucagon-receptor selective polypeptides and methods of use thereof (2023-12-12),

2. 11654183 - Methods comprising continuous administration of exenatide and co-administration of a drug (2023-05-23),

3. 11260053 - Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions (2022-03-01),

4. 11214607 - Glucagon-receptor selective polypeptides and methods of use thereof (2022-01-04),

5. 10835580 - Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug (2020-11-17),

6. 10555950 - Bile acid recycling inhibitors for treatment of obesity and diabetes (2020-02-11),

7. 10501517 - Glucagon-receptor selective polypeptides and methods of use thereof (2019-12-10),

8. 10251880 - Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions (2019-04-09),

9. 10188646 - Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions (2019-01-29),

10. 10028952 - Methods of treating diabetes or obesity using bile acids, bile salts, and mimics thereof (2018-07-24),

11. 9345715 - Methods of treating diabetes or obesity using bile acids, bile salts, and mimics thereof (2016-05-24),

12. 9339480 - Bile acid recycling inhibitors for treatment of obesity and diabetes (2016-05-17),

13. 9133260 - GIP analog and hybrid polypeptides with selectable properties (2015-09-15),

14. 8951962 - Modified exendins and exendin agonists (2015-02-10),

15. 8895498 - GIP and exendin hybrid polypeptides (2014-11-25),

Title: The Innovative Journey of Andrew A. Young

Introduction: Andrew A. Young, a distinguished inventor based in La Jolla, CA, has made significant contributions to the field of technology with his groundbreaking inventions and patents.

Latest Patents: Andrew A. Young holds several patents in the areas of artificial intelligence, renewable energy, and medical devices, showcasing his diverse range of expertise and innovative spirit.

Career Highlights: Throughout his illustrious career, Andrew A. Young has worked with leading tech companies to develop cutting-edge solutions that have revolutionized industries. His passion for innovation and problem-solving has led to the creation of products that have improved the lives of many.

Collaborations: Andrew A. Young has collaborated with top researchers, engineers, and scientists from around the world to bring his ideas to life. His ability to work in multidisciplinary teams has resulted in successful projects that have pushed the boundaries of technology.

Conclusion: In conclusion, Andrew A. Young's relentless pursuit of innovation and his commitment to excellence have established him as a prominent figure in the world of inventors. His remarkable contributions continue to inspire future generations of innovators to think outside the box and create solutions that shape the world we live in.